您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > 3-Thiatetradecanoic Acid
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
3-Thiatetradecanoic Acid
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
3-Thiatetradecanoic Acid图片
CAS NO:116296-31-2
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议

产品介绍
Cas No.116296-31-2
别名3-TDA
化学名(undecylthio)-acetic acid
Canonical SMILESCCCCCCCCCCCSCC(O)=O
分子式C13H26O2S
分子量246.4
溶解度≤30mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

3-Thiatetradecanoic Acid is an activator of PPAR.

The peroxisome proliferator-activated receptors (PPARs) are transcription factors involved in fatty acid metabolism and energy homeostasis. The PPARs also play crucial roles in the control of cellular growth and differentiation.

In vitro: In BT4Cn cells, 3-thiatetradecanoic acid could activate all PPAR subtypes dose-dependently. In cell culture experiments, the PPARγ-selective ligand BRL49653 moderately inhibited growth of BT4Cn cells, while administration of 3-thiatetradecanoic acid led to a marked growth inhibition. Moreover, the administration of the PPARγ-selective antagonist GW9662 abolished BRL49653-induced growth inhibition, but only marginally reduced the effect of 3-thiatetradecanoic acid [1].

In vivo: Administration of 3-thiatetradecanoic acid increased mitochondrial and peroxisomal beta-oxidative capacity and carnitine palmitoyltransferase activity, but reduced free fatty acid and triacylglycerol levels in plasma compared to palmitic acid-treated rats and controls. 3-Thiatetradecanoic acid administration was able to affect the fatty acid composition in plasma and liver by increasing the amount of monoenes [2].

Clinical trial: A previous study described the clinical, hematological, and biochemical safety of 3-thiatetradecanoic acid. 3-Thiatetradecanoic acid was given as a single oral dose for 7 consecutive days. No significant changes were observed in the hematological or clinical chemical parameters in blood/urine. 3-Thiatetradecanoic acid did not induce significant changes in the blood lipids or free fatty acids, but it did lead to an increase in plasma concentration of Δ9 desaturated 3-thiatetradecanoic acid. 3-thiatetradecanoic acid was found to be safe and well tolerated [3].

References:
1.  Berge K, Tronstad KJ, Flindt EN, Rasmussen TH, Madsen L, Kristiansen K, Berge RK. Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways. Carcinogenesis. 2001 Nov;22(11):1747-55.
2.  Asiedu, D.K.,Froyland, L.,Vaagenes, H., et al. Long-term effect of tetradecylthioacetic acid: A study on plasma lipid profile and fatty acid composition and oxidation in different rat organs. Biochimica et Biophysica Acta 1300, 86-96 (1996). 3. Pettersen RJ, Salem M, Skorve J, Ulvik RJ, Berge RK, Nordrehaug JE. Pharmacology and safety of tetradecylthioacetic acid (TTA): phase-1 study. J Cardiovasc Pharmacol. 2008 Apr;51(4):410-7.